73914
Sphingosine 1-phosphate
≥98.0% (TLC)
Synonym(s):
(2S,3R,4E)-2-Amino-4-octadecene-1,3-diol 1-phosphate, D-erythro-Sphingosine 1-phosphate
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C18H38NO5P
CAS Number:
Molecular Weight:
379.47
MDL number:
UNSPSC Code:
12352211
PubChem Substance ID:
NACRES:
NA.85
Recommended Products
Quality Level
Assay
≥98.0% (TLC)
form
powder
composition
carbon content, 56.97%
hydrogen content, 10.09%
nitrogen content, 3.69%
lipid type
sphingolipids
storage temp.
−20°C
SMILES string
CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O
InChI
1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1
InChI key
DUYSYHSSBDVJSM-KRWOKUGFSA-N
Looking for similar products? Visit Product Comparison Guide
Application
Repurposing Siponimod for osteoporosis: A study highlighted the potential of Siponimod, an S1P receptor modulator originally developed for multiple sclerosis, to treat osteoporosis by influencing Sphingosine 1-phosphate pathways (Hu et al., 2024).
Sphingosine-1-phosphate in ocular health: Research demonstrated that a selective agonist for Sphingosine-1-phosphate receptor 1/5 could mitigate ocular vascular pathologies, suggesting therapeutic potentials in eye disease management, it is also responsible for regulating various intracellular processes, including cell survival, differentiation, and proliferation (Nakamura et al., 2024).
Targeting diabetic kidney disease: The study investigated how Plantaginis Semen, through the sphingosine kinase 1/Sphingosine-1-phosphate pathway, could ameliorate diabetic kidney disease, underscoring the pathways role in metabolic health (Lan et al., 2024).
Advancements in neurodegenerative disease treatments: A review focused on the development of small-molecule modulators targeting Sphingosine-1-phosphate receptors, presenting new directions in treating neurodegenerative diseases (Sankar Kar et al., 2024).
Sphingosine-1-phosphate in ocular health: Research demonstrated that a selective agonist for Sphingosine-1-phosphate receptor 1/5 could mitigate ocular vascular pathologies, suggesting therapeutic potentials in eye disease management, it is also responsible for regulating various intracellular processes, including cell survival, differentiation, and proliferation (Nakamura et al., 2024).
Targeting diabetic kidney disease: The study investigated how Plantaginis Semen, through the sphingosine kinase 1/Sphingosine-1-phosphate pathway, could ameliorate diabetic kidney disease, underscoring the pathways role in metabolic health (Lan et al., 2024).
Advancements in neurodegenerative disease treatments: A review focused on the development of small-molecule modulators targeting Sphingosine-1-phosphate receptors, presenting new directions in treating neurodegenerative diseases (Sankar Kar et al., 2024).
Biochem/physiol Actions
A lipid second messenger that binds to S1P1 and S1P3 receptors. Mobilizes intracellular Ca2+ stores and decreases cellular cAMP. Activates phospholipase D. S1P stimulates the migration of endothelial cells but inhibits the migration of other cell types. Induces angiogenesis.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Craig T Wallington-Beddoe et al.
British journal of haematology, 161(5), 623-638 (2013-03-26)
The sphingosine kinases (SphKs) have relatively recently been implicated in contributing to malignant cellular processes with particular interest in the oncogenic properties of SPHK1. Whilst SPHK1 has received considerable attention as a putative oncoprotein, SPHK2 has been much more difficult
Alexander Koch et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 31(6), 745-760 (2013-06-06)
Because of its highly bioactive properties sphingosine 1-phosphate (S1P) is an attractive target for the treatment of several diseases. Since the expression of sphingosine kinases as well as S1P receptors was demonstrated in the kidney, questions about the physiological and
Roland Martin et al.
Current topics in microbiology and immunology, 378, 149-170 (2014-04-15)
The development of fingolimod, an unselective functional antagonist of the interactions between sphingosine 1 phosphate (S1P) and sphingosine 1 phosphate receptors (S1PRs), as the first oral therapy for multiple sclerosis (MS) has been a milestone. The parallel intensive research on
Tsuyoshi Nishi et al.
Biochimica et biophysica acta, 1841(5), 759-765 (2013-08-08)
Sphingosine 1-phosphate (S1P) is a lipid mediator that plays important roles in diverse cellular functions such as cell proliferation, differentiation and migration. S1P is synthesized inside the cells and subsequently released to the extracellular space, where it binds to specific
Emmanuel E Egom et al.
Current opinion in lipidology, 24(4), 351-356 (2013-05-09)
The absolute level of HDL cholesterol (HDL-C) may not be the only criterion contributing to their antiatherothrombotic effects. This review focuses on evidence in support of the concept that HDL-bound sphingosine-1-phosphate (S1P) plays a role in different HDL atheroprotective properties
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service